Product logins

Find logins to all Clarivate products below.


Mezigdomide

Learn how mezigdomide is changing the multiple myeloma landscape.

What is mezigdomide and what sets it apart

Mezigdomide is a second-generation cereblon E3 ligase modulator (CELMoD) that is designed to degrade Ikaros and Aiolos, key transcription factors in hematopoietic cell development and differentiation, resulting in both anti-myeloma and immune-stimulatory actions.

It is currently being evaluated in two global phase 3 trials in combination with other established therapies (e.g., KYPROLIS® [carfilzomib; Amgen], dexamethasone) in patients with advanced disease. Based on phase 1/2 results, it has the potential to offer new hope for patients with relapsed or refractory multiple myeloma who had previously been treated with immunomodulatory drugs (IMiDs).

About mezigdomide

  • Company: Bristol Myers Squibb
  • Type: CELMoD
  • Usage: Oral administration to treat relapsed or refractory multiple myeloma
  • When will mezigdomide be available?
    Expected launch 2026: United States
    Expected launch 2027: European Union, Japan

Mezigdomide sales and success forecasts

$1.47bn
expected sales in the G7 markets in 2031
60%
probability of success for mezigdomide in the United States

The efficacy and safety data ... reinforce the potential of CELMoD agents in combination with other standard treatments.

Anne Kerber Senior Vice President, Head of Development, Hematology, Oncology and Cell Therapy, Bristol Myers Squibb

Source: Bristol Myers Squibb, 2025

Drugs in the 2026 list

Related insights

Protein degraders enabling precision interventions for “undruggable” targets Protein degraders enabling precision interventions for “undruggable” targets
Report
Protein degraders enabling precision interventions for “undruggable” targets

Six innovators at the forefront of the emerging field of protein degrader development.

Targeting the “Undruggable”: Emerging Degrader Modalities for Novel Target Identification and Validation Targeting the “Undruggable”: Emerging Degrader Modalities for Novel Target Identification and Validation
Webinar
Targeting the “Undruggable”: Emerging Degrader Modalities for Novel Target Identification and Validation

A significant portion of disease-relevant proteins remain “undruggable” by traditional therapeutic approaches, representing a major hurdle in drug discovery. Targeted protein degradation (TPD) is rapidly advancing as a strategy to overcome this challenge, enabling the selective elimination of previously inaccessible proteins. In this on-demand webinar, experts from Clarivate, Nurix Therapeutics, Triana, and Monte Rosa Therapeutics...

Pharma is placing bigger bets on fewer, more strategic assets/platforms Pharma is placing bigger bets on fewer, more strategic assets/platforms
Blog May 28, 2025
Pharma is placing bigger bets on fewer, more strategic assets/platforms

Looming patent cliffs drove the highest recorded deal values in 2024, as pharmas continued a strategic shift towards making fewer but higher-stakes transactions. However, geopolitical uncertainty has put a damper on investment.

chevron_left
chevron_right